세계의 내분비 치료제 시장 규모 조사 및 예측 : 치료 분야별(당뇨병 치료제, HGH, 갑상선 호르몬 장애, 기타), 유통 채널별(병원 약국, 소매 약국, 온라인 약국), 지역별 분석(2023-2030년)

Global Endocrinology Drugs Market is valued at approximately USD 25084.24 million in 2022 and is anticipated to grow with a healthy growth rate of more than 7.82% over the forecast period 2023-2030. Endocrinology drugs deals with endocrine disorders, which are related to hormone imbalance and dysfunction in the endocrine system. Endocrinology drugs play an important role in providing therapeutic options for patients suffering from the endocrine disorder. The endocrinology drug market is being driven by factors such as Growing clinical trials of endocrinology drugs and rising endocrine disorders such as diabetes and thyroid.

Endocrinology drugs used to treat diabetes include insulin, which is a hormone that helps regulate blood sugar levels, and oral hypoglycemic agents (OHAs) such as metformin, sulfonylureas, and meglitinides. These drugs are designed to lower blood sugar levels and prevent complications associated with diabetes. According to the World health organization 537 million people lining with diabetes in 2021 and projections show this number is rising to 783 million people diabetic by 2045. Thus, rising in endocrine disorders fuels the market growth. In addition, advanced drug development and a growing aging population are creating a lucrative opportunity for market growth. However, Patent expiry on major endocrinology drugs is the major challenge impeding the endocrinology drugs market growth during the forecast years 2023-2030.

The key regions considered for the Global Endocrinology Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 due to high healthcare expenses and a high level of awareness in public, USA spends around 17.8% of the total GDP on healthcare. Where Asia Pacific is expected to have significant growth owing to factors such as rising disease prevalence, rising healthcare expenditure, a rapidly growing population and Government initiatives.

Major market players included in this report are:

• Abbott Laboratories
• Acerus Pharmaceuticals Corp.
• Hanmi Pharm Co. Ltd.
• Oramed Pharmaceuticals Inc.
• Pfizer Inc.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Biocon Ltd.
• Ascendis Pharma AS
• Endo International Plc

Recent Developments in the Market:

• On February 2022, Biocon announced the acquisition of Viatris' biosimilar portfolio for USD 3.335 billion. This acquisition strengthened Biocon's biosimilar product portfolio and improved its revenue generation.
• In Aug 2021, The U.S. Food and Drug Administration (FDA) approved an expanded label for Eli Lilly and Company's rapid-acting Endocrinology Drugs, Lyumjev® (Endocrinology Drugs lispro-AABC injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous Endocrinology Drugs infusion (CSII) with an Endocrinology Drugs pump.
• In July 2021, Semglee, a first-of-its-kind Endocrinology Drugs product made by India's Biocon, gets United States approval. Semglee, manufactured by Biocon Biologics, a Bengaluru-based pharmaceutical company, is both interchangeable with and biosimilar to Lantus, a long-acting Endocrinology Drugs product already approved in the United States.

Global Endocrinology Drugs Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Therapy Area, Distribution Channel, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapy Area:

• Diabetes drugs
• HGH
• Thyroid hormone disorders
• Others

By Distribution Channel:

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Million)
  • 1.2.1. Endocrinology Drugs Market, by Region, 2020-2030 (USD Million)
  • 1.2.2. Endocrinology Drugs Market, by Therapy Area, 2020-2030 (USD Million)
  • 1.2.3. Endocrinology Drugs Market, by Distribution Channel , 2020-2030 (USD Million)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Endocrinology Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Endocrinology Drugs Market Dynamics

• 3.1. Endocrinology Drugs Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Growing clinical trials for development of endocrinology drugs
    • 3.1.1.2. Growing prevalence of endocrine disorder
  • 3.1.2. Market Challenges
    • 3.1.2.1. Expiry of patents
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Advancement in drug development activities
    • 3.1.3.2. Growing aging population

Chapter 4. Global Endocrinology Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Endocrinology Drugs Market, by Therapy Area

• 5.1. Market Snapshot
• 5.2. Global Endocrinology Drugs Market by Therapy Area, Performance - Potential Analysis
• 5.3. Global Endocrinology Drugs Market Estimates & Forecasts by Therapy Area 2020-2030 (USD Million)
• 5.4. Endocrinology Drugs Market, Sub Segment Analysis
  • 5.4.1. Diabetes drug
  • 5.4.2. HGH
  • 5.4.3. Thyroid hormone disorder
  • 5.4.4. Other

Chapter 6. Global Endocrinology Drugs Market, by Distribution Channel

• 6.1. Market Snapshot
• 6.2. Global Endocrinology Drugs Market by Distribution Channel, Performance - Potential Analysis
• 6.3. Global Endocrinology Drugs Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Million)
• 6.4. Endocrinology Drugs Market, Sub Segment Analysis
  • 6.4.1. Hospital pharmacies
  • 6.4.2. Retail pharmacies
  • 6.4.3. Online pharmacies

Chapter 7. Global Endocrinology Drugs Market, Regional Analysis

• 7.1. Top Leading Countries
• 7.2. Top Emerging Countries
• 7.3. Endocrinology Drugs Market, Regional Market Snapshot
• 7.4. North America Endocrinology Drugs Market
  • 7.4.1. U.S. Endocrinology Drugs Market
    • 7.4.1.1. Therapy Area breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2. Distribution ChannelChannel breakdown estimates & forecasts, 2020-2030
  • 7.4.2. Canada Endocrinology Drugs Market
• 7.5. Europe Endocrinology Drugs Market Snapshot
  • 7.5.1. U.K. Endocrinology Drugs Market
  • 7.5.2. Germany Endocrinology Drugs Market
  • 7.5.3. France Endocrinology Drugs Market
  • 7.5.4. Spain Endocrinology Drugs Market
  • 7.5.5. Italy Endocrinology Drugs Market
  • 7.5.6. Rest of Europe Endocrinology Drugs Market
• 7.6. Asia-Pacific Endocrinology Drugs Market Snapshot
  • 7.6.1. China Endocrinology Drugs Market
  • 7.6.2. India Endocrinology Drugs Market
  • 7.6.3. Japan Endocrinology Drugs Market
  • 7.6.4. Australia Endocrinology Drugs Market
  • 7.6.5. South Korea Endocrinology Drugs Market
  • 7.6.6. Rest of Asia Pacific Endocrinology Drugs Market
• 7.7. Latin America Endocrinology Drugs Market Snapshot
  • 7.7.1. Brazil Endocrinology Drugs Market
  • 7.7.2. Mexico Endocrinology Drugs Market
• 7.8. Middle East & Africa Endocrinology Drugs Market
  • 7.8.1. Saudi Arabia Endocrinology Drugs Market
  • 7.8.2. South Africa Endocrinology Drugs Market
  • 7.8.3. Rest of Middle East & Africa Endocrinology Drugs Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Company 1
  • 8.1.2. Company 2
  • 8.1.3. Company 3
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Abbott Laboratories
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Recent Developments
  • 8.3.2. Acerus Pharmaceuticals corp.
  • 8.3.3. Hanmi Pharm co. Ltd
  • 8.3.4. Oramed Pharmaceuticals
  • 8.3.5. Pfizer Inc.
  • 8.3.6. F. Hoffmann La Roche Ltd.
  • 8.3.7. Glaosmithkline Plc
  • 8.3.8. Biocon Ltd.
  • 8.3.9. Ascendis Pharma AS
  • 8.3.10. Endo Inernational Plc

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes
• 9.3. Research Assumption